var data={"title":"Vitamin K (phytonadione): Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Vitamin K (phytonadione): Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6776?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=vitamin-k-phytonadione-drug-information\" class=\"drug drug_general\">see &quot;Vitamin K (phytonadione): Drug information&quot;</a> and <a href=\"topic.htm?path=vitamin-k-phytonadione-patient-drug-information\" class=\"drug drug_patient\">see &quot;Vitamin K (phytonadione): Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5709210\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Hypersensitivity/anaphylactoid reactions (injection): </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Severe reactions, including fatalities, have occurred during and immediately after intravenous (IV) injection of phytonadione, even when precautions have been taken to dilute the phytonadione and to avoid rapid infusion. Severe reactions, including fatalities, also have been reported following intramuscular (IM) administration. Typically, these severe reactions have resembled hypersensitivity or anaphylaxis, including shock and cardiac or respiratory arrest. Some patients have exhibited these severe reactions on receiving phytonadione for the first time. Therefore, restrict the IV and IM routes to those situations where the subcutaneous route is not feasible and the serious risk involved is considered justified.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F209759\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Mephyton</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F209760\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>AquaMEPHYTON;</li>\n      <li>Konakion;</li>\n      <li>Mephyton</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1061083\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Nutritional Supplement</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Vitamin, Fat Soluble</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11444748\" class=\"block don drugH1Div\"><span class=\"drugH1\">Dosing: Neonatal</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Dosing presented in <b>mcg</b> and mg; verify dosing units.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Adequate intake</b> (Vanek 2012): Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Preterm neonates: 8 to 10 <b>mcg</b>/kg/day</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Term neonates: 2 <b>mcg</b>/day</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Parenteral nutrition, maintenance requirement</b> (Vanek 2012): IV:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Preterm neonate: 10 <b>mcg</b>/kg/day</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Term neonates: 200 <b>mcg</b>/day</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Vitamin K deficiency bleeding (formerly known as hemorrhagic disease of the newborn): </b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Prophylaxis:</i> IM: <b>Note:</b> Administer within 1 hour of birth</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">AAP recommendations (AAP 2003; AAP 2009; AAP 2013):</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Preterm neonate: Optimal dose not established (AAP 2003)</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Birth weight &lt;1,000 g: 0.3 to 0.5 mg/kg</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Birth weight &ge;1,000 g: 0.5 to 1 mg</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Term neonate: 0.5 to 1 mg</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Alternate dosing: GA &lt;32 weeks: 0.2 mg; may repeat dose for prolonged prothrombin time or clinical signs of bleeding (Clarke 2006)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Treatment:</i> SubQ, IM: 1 to 2 mg/day</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1061078\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=vitamin-k-phytonadione-drug-information\" class=\"drug drug_general\">see &quot;Vitamin K (phytonadione): Drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Route of administration varies with indication; careful evaluation of route of administration is important. The oral route is preferred in the treatment of <b>nonbleeding</b> patients with warfarin-associated coagulopathy; SubQ administration has fallen out of favor for this indication due to erratic and unpredictable absorption (Crowther 2002; DeZee 2006; Raj 1999). The IV route may be used in select <b>nonbleeding</b> patients and should be used in patients with <b>major bleeding</b> due to warfarin-associated coagulopathy (Bolton-Maggs 2002; CHEST [Monagle 2012]). The IV and SubQ routes may be used in the treatment of vitamin K deficiency bleeding (Kliegman 2016). The IM route should be avoided due to the risk of hematoma formation except in the prevention/treatment of vitamin K deficiency bleeding (Kliegman 2016). Dosing presented in <b>mcg</b> and mg; verify dosing units.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Adequate intake</b> (IOM 2001; Vanek 2012):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">1 to 6 months: 2 <b>mcg</b>/day</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">7 to 12 months: 2.5 <b>mcg</b>/day</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">1 to 3 years: 30 <b>mcg</b>/day</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">4 to 8 years: 55 <b>mcg</b>/day</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">9 to 13 years: 60 <b>mcg</b>/day</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">14 to 18 years: 75 <b>mcg</b>/day</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Vitamin K deficiency, prevention, and supplementation (Disease-specific):</b> Limited data available:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Biliary atresia</i> (Shneider 2012): <b>Note:</b> Dose and route are determined by INR value: Infants 1 to 6 months:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">INR &gt;1.2 to 1.5: 2.5 mg once daily orally</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">INR &gt;1.5 to 1.8: Initial: 2 to 5 mg IM once followed by 2.5 mg once daily orally</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">INR &gt;1.8: Initial: 2 to 5 mg IM once followed by 5 mg once daily orally</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Cholestasis:</i> Infants, Children, and Adolescents: Oral: 2.4 to 15 mg/day (Sathe 2010)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Cystic fibrosis:</i> Infants, Children, and Adolescents: Oral: 0.3 to 0.5 mg/day (Borowitz 2002; Sathe 2010)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Liver disease:</i> Infants, Children, and Adolescents: Oral: 2.5 to 5 mg/day (Nightingale 2009; Sathe 2010)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Reversal of Vitamin K antagonists (eg, warfarin):</b> Limited data available: Infants, Children, and Adolescents:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Weight-based dosing (preferred): <i>Chest</i> recommendations: IV: 0.03 mg/kg/dose is recommended for excessively prolonged INR (usually INR &gt;8; no evidence of bleeding) due to vitamin K-antagonist (eg, warfarin): if significant bleeding, consider use of fresh frozen plasma, prothrombin complex concentrates, or recombinant factor VIIa (Bolton-Maggs 2002; Monagle 2012)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Alternate dosing: Fixed dosing: <b>Note:</b> Smaller pediatric patients should receive doses on the low end of dosing range; excessive dosages may cause warfarin-resistance (Bolton-Maggs 2002; Michelson 1998)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">No bleeding, rapid reversal needed, patient will require further oral anticoagulant therapy: SubQ, IV: 0.5 to 2 mg</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">No bleeding, rapid reversal needed, patient will not require further oral anticoagulant therapy: SubQ, IV: 2 to 5 mg</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Significant bleeding, not life-threatening: SubQ, IV: 0.5 to 2 mg</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Significant bleeding, life-threatening: SubQ, IV: 5 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Parenteral nutrition, maintenance requirement:</b> Limited data available (Vanek 2012): IV: <b>Note:</b> Patients receiving warfarin may not require TPN supplementation of phytonadione.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infants: 10 <b>mcg</b>/kg/day</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children and Adolescents: 200 <b>mcg</b>/day</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Adequate intake</b> (IOM 2001):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Male: 120 <b>mcg</b>/day</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Female: 90 <b>mcg</b>/day</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Pregnant, &le;18 years of age: 75 <b>mcg</b>/day</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Pregnant, &ge;19 years of age: 90 <b>mcg</b>/day</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Breastfeeding, &le;18 years of age: 75 <b>mcg</b>/day</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Breastfeeding, &ge;19 years of age: 90 <b>mcg</b>/day</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Vitamin K deficiency due to drugs (other than coumarin derivatives) or factors limiting absorption or synthesis:</b> Oral, SubQ, IM, IV: Initial: 2.5 to 25 mg (rarely up to 50 mg)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Vitamin K deficiency (supratherapeutic INR) secondary to VKAs (eg, warfarin): </b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>If INR above therapeutic range to &lt;4.5 (no evidence of bleeding):</i> Lower or hold next VKA dose and monitor frequently; when INR approaches desired range, resume VKA dosing with a lower dose (Patriquin 2011)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>If INR 4.5 to 10 (no evidence of bleeding):</i> The 2012 <i>Chest</i> guidelines recommend against routine phytonadione (ie, vitamin K) administration in this setting (Guyatt 2012). Previously, the 2008 ACCP guidelines recommended if no risk factors for bleeding exist, to omit next 1 or 2 VKA doses, monitor INR more frequently, and resume with an appropriately adjusted VKA dose when INR in desired range; may consider administering vitamin K orally 1 to 2.5 mg if other risk factors for bleeding exist (Hirsh 2008). Others have recommended consideration of vitamin K 1 mg orally or 0.5 mg IV (Patriquin 2011).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>If INR &gt;10 (no evidence of bleeding):</i> The 2012 ACCP guidelines recommend administration of oral vitamin K (dose not specified) in this setting (Guyatt 2012). Previously, the 2008 ACCP guidelines recommended to hold warfarin, administer vitamin K orally 2.5 to 5 mg, expect INR to be reduced within 24 to 48 hours, monitor INR more frequently and give additional vitamin K at an appropriate dose if necessary; resume warfarin at an appropriately adjusted dose when INR is in desired range (Hirsh 2008). Others have recommended consideration of vitamin K 2 to 2.5 mg orally or 0.5 to 1 mg IV (Patriquin 2011).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>If minor bleeding at any INR elevation:</i> Hold warfarin, may administer vitamin K orally 2.5 to 5 mg, monitor INR more frequently, may repeat dose after 24 hours if INR correction incomplete; resume warfarin at an appropriately adjusted dose when INR is in desired range (Patriquin 2011)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>If major bleeding at any INR elevation:</i> The 2012 ACCP guidelines recommend administration of four-factor prothrombin complex concentrate (PCC) and IV vitamin K 5 to 10 mg in this setting (Guyatt 2012); however, in the US, the available PCCs (Bebulin VH and Profilnine SD) are <b>three</b>-factor PCCs and do not contain adequate levels of factor VII. Four-factor PCCs include Beriplex P/N, Cofact, Konyne, or Octaplex all of which are <b>not</b> available in the US. Previously, the 2008 ACCP guidelines recommended to hold warfarin, administer vitamin K 10 mg by slow IV infusion and supplement with PCC depending on the urgency of the situation; IV vitamin K may be repeated every 12 hours (Hirsh 2008).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>Note:</b> Use of high doses of vitamin K (eg, 10 to 15 mg) may cause warfarin resistance for &ge;1 week. During this period of resistance, heparin or low molecular-weight heparin (LMWH) may be given until INR responds (Ansell 2008).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Preprocedural/surgical INR normalization in patients receiving warfarin (routine use):</b> Oral: 1 to 2.5 mg once administered on the day before surgery; recheck INR on day of procedure/surgery (Douketis 2012). Others have recommended the use of vitamin K 1 mg orally for mild INR elevations (ie, INR 3.0 to 4.5) (Patriquin 2011).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F209741\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Injection, aqueous colloidal: 1 mg/0.5 mL (0.5 mL); 10 mg/mL (1 mL) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Injection, aqueous colloidal [preservative free]: 1 mg/0.5 mL (0.5 mL) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, oral: 100 mcg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Mephyton&reg;: 5 mg [scored]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F209727\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25572881\" class=\"block dosfc drugH1Div\"><span class=\"drugH1\">Dosage Forms Considerations</span><p>(For additional information <a href=\"topic.htm?path=vitamin-k-phytonadione-drug-information\" class=\"drug drug_general\">see &quot;Vitamin K (phytonadione): Drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">Injectable products may contain alcohol, benzyl alcohol, polysorbate 80, propylene glycol, or polyoxyethylated/polyethoxylated castor oil (Cremophor EL).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1061087\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral: May be administered with or without food. The parenteral formulation may also be used for small oral doses (eg, 1 mg) or situations in which tablets cannot be swallowed (Crowther 2000; O'Connor 1986).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Parenteral: <b>Note:</b> Limit IV administration to situations where an alternative route of administration is not feasible and the benefit of therapy outweighs the risk of hypersensitivity reactions; proper dosing, dilution, and administration will minimize risk (Ageno 2012; Riegert-Johnson 2002). Allergic reactions have also occurred with IM and SubQ injections, albeit less frequently.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">SubQ: Administer undiluted.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IM: Administer undiluted; for use in neonatal patients, verify appropriate concentration (1 mg/0.5 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IV: After dilution, infuse slowly. In pediatric patients, IV doses have been infused over 15 to 30 minutes (Kliegman 2007; Michelson 1998); in adults, administration using an infusion pump over at least 20 minutes has been suggested (Ageno 2012); maximum rate of infusion: 1 mg/minute</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F209756\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Injection: Store at 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F). Protect from light. <b>Note:</b> Store Hospira product at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral: Store tablets at 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F). Protect from light. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1061086\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Injection: Prophylaxis and treatment of hemorrhagic disease of the newborn (FDA approved in newborns); prevention and treatment of hypoprothrombinemia caused by vitamin K deficiency, vitamin K antagonist (VKA)-induced (eg, warfarin-induced), other drug-induced vitamin K deficiency, altered activity, or altered metabolism (FDA approved in adults); hypoprothrombinemia caused by malabsorption or inability to synthesize vitamin K (FDA approved in adults)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral: Prevention and treatment of hypoprothrombinemia caused by vitamin K deficiency, vitamin K antagonist (VKA)-induced (eg, warfarin-induced), other drug-induced vitamin K deficiency, altered activity, or altered metabolism; hypoprothrombinemia caused by malabsorption or inability to synthesize vitamin K (FDA approved in adults)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F209808\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Mephyton may be confused with melphalan, methadone</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F209807\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiovascular: Flushing, hypertension, hypotension</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Dizziness</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Diaphoresis, erythematous rash, pruritus</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Dysgeusia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity: Anaphylactoid reaction (non-immunologic anaphylaxis), hypersensitivity reaction</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Local: Fibrosis at injection site, injection site reaction</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Respiratory: Cyanosis, dyspnea</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F209748\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to phytonadione or any component of the formulation</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F209731\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypersensitivity/anaphylactoid reactions: <b> [US Boxed Warning]: Severe reactions resembling hypersensitivity reactions (eg, anaphylaxis) have occurred rarely during or immediately after IV administration (even with proper dilution and rate of administration); some patients had no previous exposure to phytonadione.</b> Anaphylactoid reactions typically occurred when patients received large IV doses administered rapidly with formulations containing polyethoxylated castor oil (also called polyoxyethylated castor oil); proper dosing, dilution, and administration will minimize risk (Ageno 2012; Riegert-Johnson 2002). Limit IV administration to situations where an alternative route of administration is not feasible and the benefit of therapy outweighs the risk of hypersensitivity reactions. Allergic reactions have also occurred with IM and SubQ injections, albeit less frequently.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Anticoagulant-induced hypoprothrombinemia: In patients receiving a therapeutic vitamin K antagonist (VKA) (eg, warfarin), administer a dose of phytonadione that will quickly lower the INR into a safe range without causing resistance to warfarin. High phytonadione doses may lead to warfarin resistance for at least one week.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Liver disease induced hypoprothrombinemia: If initial doses do not reverse coagulopathy, then higher doses are unlikely to have any effect. <b>Note:</b> Ineffective in hereditary hypoprothrombinemia.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Long-acting anticoagulant rodenticide (LAAR) ingestion: Patients with LAAR-induced coagulopathy require much larger doses and longer treatment durations (up to months) after exposure compared to that needed to reverse VKA-induced coagulopathy.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Neonates: Use with caution in neonates, especially premature infants; severe hemolytic anemia, jaundice, and hyperbilirubinemia have been reported with larger than recommended doses (10 to 20 mg).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Aluminum: The parenteral product may contain aluminum; toxic aluminum concentrations may be seen with high doses, prolonged use, or renal dysfunction. Premature neonates are at higher risk due to immature renal function and aluminum intake from other parenteral sources. Parenteral aluminum exposure of &gt;4 to 5 mcg/kg/day is associated with CNS and bone toxicity; tissue loading may occur at lower doses (Federal Register 2002). See manufacturer&rsquo;s labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Benzyl alcohol and derivatives: Some dosage forms may contain benzyl alcohol; large amounts of benzyl alcohol (&ge;99 mg/kg/day) have been associated with a potentially fatal toxicity (&ldquo;gasping syndrome&rdquo;) in neonates; the &ldquo;gasping syndrome&rdquo; consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension, and cardiovascular collapse (AAP [&quot;Inactive&quot; 1997]; CDC 1982); some data suggests that benzoate displaces bilirubin from protein binding sites (Ahlfors 2001); avoid or use dosage forms containing benzyl alcohol with caution in neonates. See manufacturer&rsquo;s labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Polyoxyethylated castor oil: Some injectable dosage forms contain polyoxyethylated castor oil (Cremophor EL) which is associated with hypersensitivity reactions.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Polysorbate 80: Some dosage forms may contain polysorbate 80 (also known as Tweens). Hypersensitivity reactions, usually a delayed reaction, have been reported following exposure to pharmaceutical products containing polysorbate 80 in certain individuals (Isaksson 2002; Lucente 2000; Shelley 1995). Thrombocytopenia, ascites, pulmonary deterioration, and renal and hepatic failure have been reported in premature neonates after receiving parenteral products containing polysorbate 80 (Alade 1986; CDC 1984). See manufacturer&rsquo;s labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate route: Oral administration is the safest and requires the presence of bile salts for absorption. In obstructive jaundice or with biliary fistulas, concurrent administration of bile salts would be necessary for proper absorption. Manufacturers recommend the SubQ route over other parenteral routes, however, SubQ is less predictable when compared to the oral route, and efficacy may be delayed. Therefore, the SubQ route has fallen out of favor due to erratic and unpredictable absorption (Crowther 2002; DeZee 2006; Raj 1999). The IV route may be used in selected <b>nonbleeding</b> patients and should be used in patients with <b>major bleeding</b> due to warfarin-associated coagulopathy (ACCP [Guyatt 2012]; Patriquin 2011). IM route should be avoided due to the risk of hematoma formation (except, for example, in the neonatal and pediatric populations for prevention/treatment of vitamin K deficiency bleeding). Efficacy (eg, control of bleeding, decrease in INR) is delayed regardless of route of administration; patient management may require other treatments in the interim.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299879\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F209735\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=12704&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Mineral Oil: May decrease the serum concentration of Phytonadione. Specifically, mineral oil may decrease the absorption of phytonadione.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Orlistat: May decrease the serum concentration of Vitamins (Fat Soluble). Management: Administer oral fat soluble vitamins at least 2 hours before or after the administration of orlistat.  Similar precautions do not apply to parenterally administered fat soluble vitamins.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vitamin K Antagonists (eg, warfarin): Phytonadione may diminish the anticoagulant effect of Vitamin K Antagonists. <i> Risk D: Consider therapy modification</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F209737\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10916304\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Animal reproduction studies have not been conducted. Phytonadione crosses the placenta in limited concentrations (Kazzi, 1990). The dietary requirements of vitamin K are the same in pregnant and nonpregnant women (IOM 2000). In general, medications used as antidotes should take into consideration the health and prognosis of the mother; antidotes should be administered to pregnant women if there is a clear indication for use and should not be withheld because of fears of teratogenicity (Bailey 2003).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1061082\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">PT, INR</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F209730\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Promotes liver synthesis of clotting factors (II, VII, IX, X); however, the exact mechanism as to this stimulation is unknown. Menadiol is a water soluble form of vitamin K; phytonadione has a more rapid and prolonged effect than menadione; menadiol sodium diphosphate (K<sub>4</sub>) is half as potent as menadione (K<sub>3</sub>).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F209747\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Onset of action: Increased coagulation factors: Oral: 6 to 10 hours; IV: 1 to 2 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Peak effect: INR values return to normal: Oral: 24 to 48 hours; IV: 12 to 14 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption: Oral: From intestines in presence of bile; SubQ: Variable; IM: Readily</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Rapidly hepatic </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Urine and feces</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F209746\" class=\"block exp drugH1Div\"><span class=\"drugH1\">Extemporaneous Preparations</span>\n    <p style=\"text-indent:0em;display:inline\">A 1 mg/mL oral suspension may be made with tablets. Crush six 5 mg tablets in a mortar and reduce to a fine powder. Add 5 mL each of water and methylcellulose 1% and mix to a uniform paste. Mix while adding sorbitol in incremental proportions to <b>almost</b> 30 mL; transfer to a calibrated bottle, rinse mortar with sorbitol, and add quantity of sorbitol sufficient to make 30 mL. Label &quot;shake well&quot; and &quot;refrigerate&quot;. Stable for 3 days.</p>\n    <div class=\"reference\">Nahata MC and Hipple TF, <i>Pediatric Drug Formulations</i>, 3rd ed, Cincinnati, OH: Harvey Whitney Books Co, 1997.</div>\r\n\n    <p style=\"text-indent:0em;\">\n      <b>Note:</b> The parenteral formulation may also be used for small oral doses (eg, 1 mg) or situations in which tablets cannot be swallowed (Crowther, 2000; O&rsquo;Connor, 1986); may administer undiluted or diluted in a beverage (eg, orange juice) (Vanier 2006).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F209750\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Phytonadione Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 mg/0.5 mL (0.5 mL): $21.60</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Mephyton Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5 mg (100): $7,051.21</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F209751\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Bonadiona (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Haemokion (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);</li>\n      <li>Hema-K (PH);</li>\n      <li>Kanakion (PT);</li>\n      <li>Kanavit (CZ);</li>\n      <li>Katimin-1 (TW);</li>\n      <li>Kenadion (IN);</li>\n      <li>Konakion (10 mg) (AE, AU, BG, BH, CY, DE, EC, EG, GB, GH, IE, IL, IQ, IR, IT, JO, KE, KW, LB, LY, NL, OM, QA, SA, SE, SY, TZ, UG, YE, ZM);</li>\n      <li>Konakion (BE, DK, ES, HU, IS, LU, NO, SI, TR, ZW);</li>\n      <li>Konakion 10 mg (AT, FI, HN);</li>\n      <li>Konakion MM (BH, CL, HR, KW, LB, LK, LV, MX);</li>\n      <li>Konakion MM Paediatric (BB, BM, BS, BZ, GY, JM, SR, TT);</li>\n      <li>Konakion MM Pediatric (AR, AU, BR, CH, CO, NZ, PE, PK, PY, UY, VN);</li>\n      <li>Neokay (GB);</li>\n      <li>Phytomen (PH);</li>\n      <li>Prohem (ID);</li>\n      <li>Univitan K1 (HK);</li>\n      <li>Vitacon (PL);</li>\n      <li>Vitak (JP);</li>\n      <li>Vitamin K (HK);</li>\n      <li>Vitamin K1 (KR);</li>\n      <li>Vitamine K!1 Roche (FR);</li>\n      <li>Vitka Infant (ID)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Ageno W, Gallus AS, Wittkowsky A, et al, &ldquo;Oral Anticoagulant Therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines,&rdquo; <i>Chest</i>, 2012, 141(2 Suppl):e44-88.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vitamin-k-phytonadione-pediatric-drug-information/abstract-text/22315269/pubmed\" target=\"_blank\" id=\"22315269\">22315269</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ahlfors CE. Benzyl alcohol, kernicterus, and unbound bilirubin. <i>J Pediatr</i>. 2001;139(2):317-319.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vitamin-k-phytonadione-pediatric-drug-information/abstract-text/11487763 /pubmed\" target=\"_blank\" id=\"11487763 \">11487763 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Alade SL, Brown RE, Paquet A. Polysorbate 80 and E-Ferol toxicity. <i>Pediatrics</i>. 1986;77(4):593-597.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vitamin-k-phytonadione-pediatric-drug-information/abstract-text/3960626/pubmed\" target=\"_blank\" id=\"3960626\">3960626</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Aluminum in large and small volume parenterals used in total parenteral nutrition. <i>Fed Regist</i>. 2002;67(244):77792-77793.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Academy of Pediatrics Committee on Drugs. &quot;Inactive&quot; ingredients in pharmaceutical products: update (subject review). <i>Pediatrics</i>. 1997;99(2):268-278.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vitamin-k-phytonadione-pediatric-drug-information/abstract-text/9024461/pubmed\" target=\"_blank\" id=\"9024461\">9024461</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Academy of Pediatrics Committee on Fetus and Newborn, &quot;Controversies Concerning Vitamin K and the Newborn. American Academy of Pediatrics Committee on Fetus and Newborn,&quot; <i>Pediatrics</i>, 2003, 112(1 Pt 1):191-2.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vitamin-k-phytonadione-pediatric-drug-information/abstract-text/12837888/pubmed\" target=\"_blank\" id=\"12837888\">12837888</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Academy of Pediatrics, Committee on Nutrition. <i>Pediatric Nutrition Handbook</i>, 7th ed, Kleinman RE, Greer FR, eds, Elk Grove Village, IL: American Academy of Pediatrics; 2013, 510-515.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Academy of Pediatrics Committee on Nutrition, &quot;Micronutrients: Vitamin K,&quot; <i>Pediatric Nutrition Handbook</i>, 6th ed, Kleinman RE, ed, Elk Grove Village, IL: American Academy of Pediatrics, 2009, 469.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ansell J, Hirsh J, Hylek E, et al, &quot;Pharmacology and Management of the Vitamin K Antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition),&quot; <i>Chest</i>, 2008, 133(6 Suppl):160-98.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vitamin-k-phytonadione-pediatric-drug-information/abstract-text/18574265/pubmed\" target=\"_blank\" id=\"18574265\">18574265</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bailey B, &quot;Are There Teratogenic Risks Associated With Antidotes Used in the Acute Management of Poisoned Pregnant Women?&quot; <i>Birth Defects Res A Clin Mol Teratol</i>, 2003, 67(2):133-40.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vitamin-k-phytonadione-pediatric-drug-information/abstract-text/12769509/pubmed\" target=\"_blank\" id=\"12769509\">12769509</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bolton-Maggs P and Brook L, &quot;The Use of Vitamin K for Reversal of Over-Warfarinization in Children,&quot; <i>Br J Haematol</i>, 2002, 118(3):924.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vitamin-k-phytonadione-pediatric-drug-information/abstract-text/12181071/pubmed\" target=\"_blank\" id=\"12181071\">12181071</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Borowitz D, Baker RD, and Stallings V, &quot;Consensus Report on Nutrition for Pediatric Patients With Cystic Fibrosis,&quot; <i>J Pediatr Gastroenterol Nutr</i>, 2002, 35(3):246-59.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vitamin-k-phytonadione-pediatric-drug-information/abstract-text/12352509/pubmed\" target=\"_blank\" id=\"12352509\">12352509</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control (CDC). Neonatal deaths associated with use of benzyl alcohol - United States. <i>MMWR Morb Mortal Wkly Rep</i>. 1982;31(22):290-291. Available at <a href=\"http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm\" target=\"_blank\">http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm</a><span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vitamin-k-phytonadione-pediatric-drug-information/abstract-text/6810084 /pubmed\" target=\"_blank\" id=\"6810084 \">6810084 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control (CDC). Unusual syndrome with fatalities among premature infants: association with a new intravenous vitamin E product. <i>MMWR Morb Mortal Wkly Rep</i>. 1984;33(14):198-199 <a href=\"http://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm\" target=\"_blank\">http://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm</a><span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vitamin-k-phytonadione-pediatric-drug-information/abstract-text/6423951/pubmed\" target=\"_blank\" id=\"6423951\">6423951</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Clarke P, Mitchell SJ, Wynn R, et al, &quot;Vitamin K Prophylaxis for Preterm Infants: A Randomized, Controlled Trial of 3 Regimens,&quot; <i>Pediatrics</i>, 2006, 118(6):e1657-66.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vitamin-k-phytonadione-pediatric-drug-information/abstract-text/17101711/pubmed\" target=\"_blank\" id=\"17101711\">17101711</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Costakos DT, Greer FR, Love LA, et al, &quot;Vitamin K Prophylaxis for Premature Infants: 1 mg Versus 0.5 mg,&quot; <i>Am J Perinatol</i>, 2003, 20(8):485-90.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vitamin-k-phytonadione-pediatric-drug-information/abstract-text/14703597/pubmed\" target=\"_blank\" id=\"14703597\">14703597</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Costakos DT, Porte M. Did &quot;controversies concerning vitamin K and the newborn&quot; cover all the controversies? <i> Pediatrics</i>. 2004;113(5):1466-1467.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vitamin-k-phytonadione-pediatric-drug-information/abstract-text/15121973 /pubmed\" target=\"_blank\" id=\"15121973 \">15121973 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Crowther MA, Douketis JD, Schnurr T, et al. Oral vitamin K lowers the international normalized ratio more rapidly than subcutaneous vitamin K in the treatment of warfarin-associated coagulopathy. A randomized, controlled trial. <i>Ann Intern Med</i>. 2002;137(4):251-254.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vitamin-k-phytonadione-pediatric-drug-information/abstract-text/12186515/pubmed\" target=\"_blank\" id=\"12186515\">12186515</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Crowther MA, Julian J, McCarty D, et al, &quot;Treatment of Warfarin-Associated Coagulopathy With Oral Vitamin K: A Randomised Controlled Trial,&quot;<i> Lancet</i>, 2000, 356(9241):1551-3.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vitamin-k-phytonadione-pediatric-drug-information/abstract-text/11075768/pubmed\" target=\"_blank\" id=\"11075768\">11075768</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Department Health &amp; Human Services, Food Drug Administration, &quot;Aluminum in Large and Small Volume Parenterals Used in Total Parenteral Nutrition,&quot; <i>Federal Register</i>, 2000, 65(17):4103-11.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dezee KJ, Shimeall WT, Douglas KM, Shumway NM, O'malley PG. Treatment of excessive anticoagulation with phytonadione (vitamin K): a meta-analysis. <i>Arch Intern Med</i>. 2006;166(4):391-397.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vitamin-k-phytonadione-pediatric-drug-information/abstract-text/16505257/pubmed\" target=\"_blank\" id=\"16505257\">16505257</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Douketis JD, Spyropoulos AC, Spencer FA, et al, &quot;Perioperative Management of Antithrombotic Therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines,&quot; <i>Chest</i>, 2012, 141(2 Suppl):e326-50.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vitamin-k-phytonadione-pediatric-drug-information/abstract-text/22315266/pubmed\" target=\"_blank\" id=\"22315266\">22315266</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Guyatt GH, Akl EA, Crowther M, et al, &quot;Executive Summary: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines,&quot; <i>Chest</i>, 2012, 141(2 Suppl):7-47.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vitamin-k-phytonadione-pediatric-drug-information/abstract-text/22315257/pubmed\" target=\"_blank\" id=\"22315257\">22315257</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hirsh J, Guyatt G, Albers GW, et al, &quot;Executive Summary: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition), <i>Chest</i>, 2008, 133(6 Suppl):71-109.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vitamin-k-phytonadione-pediatric-drug-information/abstract-text/18574259/pubmed\" target=\"_blank\" id=\"18574259\">18574259</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    IOM (Institute of Medicine), <i>Dietary Reference Intakes for Vitamin A, Vitamin K, Arsenic, Boron, Chromium, Copper, Iodine, Iron, Manganese, Molybdenum, Nickel, Silicon, Vanadium, and Zinc</i>, Washington, DC: National Academy Press, 2001.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Isaksson M, Jansson L. Contact allergy to Tween 80 in an inhalation suspension. <i>Contact Dermatitis</i>. 2002;47:313.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kazzi NJ, Ilagan NB, Liang KC, et al, &quot;Placental Transfer of Vitamin K1 in Preterm Pregnancy,&quot; <i>Obstet Gynecol</i>, 1990, 75(3 Pt 1):334-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vitamin-k-phytonadione-pediatric-drug-information/abstract-text/2304704/pubmed\" target=\"_blank\" id=\"2304704\">2304704</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kliegman RM, Behrman RE, Jenson HB, et al, eds. <i>Nelson Textbook of Pediatrics</i>. 18th ed. Philadelphia, PA: Saunders Elsevier; 2007.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kliegman RM, Stanton BMD, St. Geme J, Schor NF, eds. <i>Nelson Textbook of Pediatrics</i>. 20th ed. Philadelphia, PA: Saunders Elsevier; 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lucente P, Iorizzo M, Pazzaglia M. Contact sensitivity to Tween 80 in a child. <i>Contact Dermatitis</i>. 2000;43:172.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Michelson AD, Bovill E, Monagle P, et al, &ldquo;Antithrombic Therapy in Children,&rdquo; <i>Chest</i>, 1998, 114(5 Suppl):748-69.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vitamin-k-phytonadione-pediatric-drug-information/abstract-text/9822076/pubmed\" target=\"_blank\" id=\"9822076\">9822076</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Monagle P, Chan AK, Goldenberg NA, et al, &quot;Antithrombotic Therapy in Neonates and Children: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines,&quot; <i>Chest</i>, 2012, 141(2 Suppl):e737-801.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vitamin-k-phytonadione-pediatric-drug-information/abstract-text/22315277/pubmed\" target=\"_blank\" id=\"22315277\">22315277</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Nightingale S and Ng VL, &quot;Optimizing Nutritional Management in Children With Chronic Liver Disease,&quot; <i>Pediatr Clin North Am</i>, 2009, 56(5):1161-83.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vitamin-k-phytonadione-pediatric-drug-information/abstract-text/19931069/pubmed\" target=\"_blank\" id=\"19931069\">19931069</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    O'Connor ME and Addiego JE Jr, &quot;Use of Oral Vitamin K1 to Prevent Hemorrhagic Disease of the Newborn Infant,&quot; <i>J Pediatr</i>, 1986, 108(4):616-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vitamin-k-phytonadione-pediatric-drug-information/abstract-text/3514830/pubmed\" target=\"_blank\" id=\"3514830\">3514830</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Patriquin C and Crowther M, &quot;Treatment of Warfarin-Associated Coagulopathy With Vitamin K,&quot; <i>Expert Rev Hematol</i>, 2011, 4(6):657-65.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vitamin-k-phytonadione-pediatric-drug-information/abstract-text/22077529/pubmed\" target=\"_blank\" id=\"22077529\">22077529</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Phytonadione [prescribing information]. El Monte, CA: International Medication Systems, Limited; December 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Raj G, Kumar R, McKinney WP. Time course of reversal of anticoagulant effect of warfarin by intravenous and subcutaneous phytonadione. <i>Arch Intern Med</i>. 1999;159(22):2721-2724.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vitamin-k-phytonadione-pediatric-drug-information/abstract-text/10597763/pubmed\" target=\"_blank\" id=\"10597763\">10597763</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Riegert-Johnson DL and Volcheck GW, &ldquo;The Incidence of Anaphylaxis Following Intravenous Phytonadione (Vitamin K1): A 5-year Retrospective Review,&rdquo; <i>Ann Allergy Asthma Immunol</i>, 2002, 89(4):400-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vitamin-k-phytonadione-pediatric-drug-information/abstract-text/12392385/pubmed\" target=\"_blank\" id=\"12392385\">12392385</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sathe MN and Patel AS, &quot;Update in Pediatrics: Focus on Fat-Soluble Vitamins,&quot; <i>Nutr Clin Pract</i>, 2010, 25(4):340-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vitamin-k-phytonadione-pediatric-drug-information/abstract-text/20702838/pubmed\" target=\"_blank\" id=\"20702838\">20702838</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Shehab N, Lewis CL, Streetman DD, Donn SM. Exposure to the pharmaceutical excipients benzyl alcohol and propylene glycol among critically ill neonates. <i>Pediatr Crit Care Med</i>. 2009;10(2):256-259.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vitamin-k-phytonadione-pediatric-drug-information/abstract-text/19188870/pubmed\" target=\"_blank\" id=\"19188870\">19188870</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Shelley WB, Talanin N, Shelley ED. Polysorbate 80 hypersensitivity. <i>Lancet</i>. 1995;345(8980):1312-1313.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Shneider BL, Magee JC, Bezerra JA, et al, &quot;Efficacy of Fat-Soluble Vitamin Supplementation in Infants With Biliary Atresia,&quot; <i>Pediatrics</i>, 2012, 130(3):e607-14.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vitamin-k-phytonadione-pediatric-drug-information/abstract-text/22891232/pubmed\" target=\"_blank\" id=\"22891232\">22891232</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Vanek VW, Borum P, Buchman A, et al, &quot;A.S.P.E.N. Position Paper: Recommendations for Changes in Commercially Available Parenteral Multivitamin and Multi-trace Element Products,&quot; <i>Nutr Clin Pract</i>, 2012, 27(4):440-91.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vitamin-k-phytonadione-pediatric-drug-information/abstract-text/22730042/pubmed\" target=\"_blank\" id=\"22730042\">22730042</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 12704 Version 98.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F5709210\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F209759\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F209760\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1061083\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Neonatal\" href=\"#F11444748\" class=\"outlineLink\">Dosing: Neonatal</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1061078\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F209741\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F209727\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms Considerations\" href=\"#F25572881\" class=\"outlineLink\">Dosage Forms Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1061087\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F209756\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1061086\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F209808\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F209807\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F209748\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F209731\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299879\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F209735\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F209737\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F10916304\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F1061082\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F209730\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F209747\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Extemporaneous Preparations\" href=\"#F209746\" class=\"outlineLink\">Extemporaneous Preparations</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F209750\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F209751\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/12704|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=vitamin-k-phytonadione-drug-information\" class=\"drug drug_general\">Vitamin K (phytonadione): Drug information</a></li><li><a href=\"topic.htm?path=vitamin-k-phytonadione-patient-drug-information\" class=\"drug drug_patient\">Vitamin K (phytonadione): Patient drug information</a></li></ul></div></div>","javascript":null}